SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 9, 2022
WAVE LIFE SCIENCES LTD.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
7 Straits View #12-00, Marina One
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including area code: +65 6236 3388
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
|$0 Par Value Ordinary Shares||WVE||The Nasdaq Global Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) On August 9, 2022, the shareholders of Wave Life Sciences Ltd. (the “Company”) approved an amendment to the Company’s 2021 Equity Incentive Plan (the “Amended 2021 Plan”) that increases the number of ordinary shares authorized for issuance of awards under the Amended 2021 Plan by 6,000,000 shares.
A detailed summary of the material features of the Amended 2021 Plan is set forth in the Company’s definitive proxy statement for its 2022 Annual General Meeting of Shareholders filed with the Securities and Exchange Commission on June 29, 2022 (the “Proxy Statement”). That summary and the foregoing description are qualified in their entirety by reference to the text of the Amended 2021 Plan, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.
Submission of Matters to a Vote of Security Holders.
On August 9, 2022, the Company held its 2022 Annual General Meeting of Shareholders (the “Annual Meeting”). Of the 86,820,111 ordinary shares issued and outstanding and eligible to vote as of the meeting date of August 9, 2022, a quorum of 74,350,854 ordinary shares, or 85.6%, of the eligible shares, was present in person or represented by proxy at the Annual Meeting.
The following actions were taken at the Annual Meeting, all of which are described in the Proxy Statement. The final voting results for each of the proposals voted upon at the Annual Meeting are set forth below.
Proposal 1 (a) – (i)- Shareholders re-elected nine of the Company’s existing directors to the Board of Directors for a term ending on the Company’s 2023 Annual General Meeting of Shareholders and his or her successor is duly elected and qualified, with the final votes cast as follows:
Board of Directors Nominee
Paul B. Bolno, M.D., MBA
Mark H.N. Corrigan, M.D.
Peter Kolchinsky, Ph.D.
Aik Na Tan
Gregory L. Verdine, Ph.D.
Heidi L. Wagner, J.D.
Proposal 2- Shareholders re-appointed KPMG LLP to serve as the Company’s independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2022, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP’s remuneration for services provided through the date of the Company’s 2023 Annual General Meeting of Shareholders, with the final votes cast as follows:
Proposal 3- Shareholders approved the Company’s payment of cash and equity-based compensation to the Company’s non-employee directors for their service on the Board of Directors and its committees, in the manner and on the basis set forth in the Proxy Statement, with the final votes cast as follows:
Proposal 4- Shareholders approved the amendment to the Company’s 2021 Equity Incentive Plan, in the manner and on the basis set forth in the Proxy Statement, with the final votes cast as follows:
Proposal 5- Shareholders approved a general authorization for the directors of the Company to allot and issue ordinary shares of the Company, in the manner and on the basis set forth in the Proxy Statement, with the final votes cast as follows:
Proposal 6- Shareholders approved on a non-binding, advisory basis only, the compensation of our named executive officers, in the manner and on the basis set forth described in the proxy statement, with the final votes cast as follows:
Financial Statements and Exhibits.
|10.1||Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|WAVE LIFE SCIENCES LTD.|
/s/ Paul B. Bolno, M.D.
|Paul B. Bolno, M.D.|
|President and Chief Executive Officer|
Date: August 15, 2022